Literature DB >> 24832995

3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry.

Sebastien Anizan1, Kayla Ellefsen2, Marta Concheiro1, Masaki Suzuki3, Kenner C Rice4, Michael H Baumann5, Marilyn A Huestis6.   

Abstract

Synthetic cathinones are recreational drugs that mimic the effects of illicit stimulants like cocaine, amphetamine or Ecstasy. Among the available synthetic cathinones in the United States, 3,4-methylenedioxypyrovalerone (MDPV) is commonly abused and associated with dangerous side effects. MDPV is a dopamine transporter blocker 10-fold more potent than cocaine as a locomotor stimulant in rats. Previous in vitro and in vivo studies examining MDPV metabolism reported 3,4-dihydroxypyrovalerone (3,4-catechol-PV) and 4-hydroxy-3-methoxypyrovalerone (4-OH-3-MeO-PV) as the two primary metabolites. We developed and validated a liquid chromatography-high resolution mass spectrometry method to quantify MDPV and its primary metabolites in 100 μL human and rat plasma. Plasma hydrolysis was followed by protein precipitation before analysis. Limits of detection were 0.1 μg L(-1), with linear ranges from 0.25 to 1000 μg L(-1). Process efficiency, matrix effect, total imprecision (%CV) and accuracy (%target) were 36-93%, from -8 to 12%, 2.1 to 7.3% and 86 to 109%, respectively. MDPV and metabolites were stable at room temperature for 24 h, 4 °C for 72 h and after 3 freeze-thaw cycles with less than 10% variability. Human-rat plasma cross validation demonstrated that rat plasma could be accurately quantified against a human plasma calibration curve. As proof of this method, rat plasma specimens were analyzed after intraperitoneal and subcutaneous dosing with MDPV (0.5 mg kg(-1)). MDPV, 3,4-catechol-PV and 4-OH-3-MeO-PV concentrations ranged from not detected to 107.5 μg L(-1) prior to and up to 8h after dosing. This method provides a simultaneous quantification of MDPV and two metabolites in plasma with good selectivity and sensitivity. Published by Elsevier B.V.

Entities:  

Keywords:  HRMS; LC–MS/MS; MDPV; Metabolites; Synthetic cathinones

Mesh:

Substances:

Year:  2014        PMID: 24832995      PMCID: PMC4150738          DOI: 10.1016/j.aca.2014.04.015

Source DB:  PubMed          Journal:  Anal Chim Acta        ISSN: 0003-2670            Impact factor:   6.558


  27 in total

Review 1.  Cathinone derivatives: a review of their chemistry, pharmacology and toxicology.

Authors:  John P Kelly
Journal:  Drug Test Anal       Date:  2011-07-13       Impact factor: 3.345

2.  Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States.

Authors:  Henry A Spiller; Mark L Ryan; Robert G Weston; Joanne Jansen
Journal:  Clin Toxicol (Phila)       Date:  2011-07       Impact factor: 4.467

3.  3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans.

Authors:  M Segura; J Ortuño; M Farré; J A McLure; M Pujadas; N Pizarro; A Llebaria; J Joglar; P N Roset; J Segura; R de La Torre
Journal:  Chem Res Toxicol       Date:  2001-09       Impact factor: 3.739

4.  Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry.

Authors:  Sabina Strano-Rossi; Amy B Cadwallader; Xavier de la Torre; Francesco Botrè
Journal:  Rapid Commun Mass Spectrom       Date:  2010-09       Impact factor: 2.419

5.  Pharmacological characterization of designer cathinones in vitro.

Authors:  L D Simmler; T A Buser; M Donzelli; Y Schramm; L-H Dieu; J Huwyler; S Chaboz; M C Hoener; M E Liechti
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  Illicit bath salts: not for bathing.

Authors:  Patrick B Kyle; Richard B Iverson; Raghavendran G Gajagowni; Lee Spencer
Journal:  J Miss State Med Assoc       Date:  2011-12

7.  Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry.

Authors:  Marta Concheiro; Sebastien Anizan; Kayla Ellefsen; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-10-03       Impact factor: 4.142

8.  1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.

Authors:  Peter C Meltzer; David Butler; Jeffrey R Deschamps; Bertha K Madras
Journal:  J Med Chem       Date:  2006-02-23       Impact factor: 7.446

9.  Designer cathinones--an emerging class of novel recreational drugs.

Authors:  Jolanta B Zawilska; Jakub Wojcieszak
Journal:  Forensic Sci Int       Date:  2013-05-10       Impact factor: 2.395

10.  Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results.

Authors:  Laureen J Marinetti; Heather M Antonides
Journal:  J Anal Toxicol       Date:  2013-01-29       Impact factor: 3.367

View more
  12 in total

Review 1.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

Review 2.  Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs.

Authors:  Michael H Baumann; Mohammad O Bukhari; Kurt R Lehner; Sebastien Anizan; Kenner C Rice; Marta Concheiro; Marilyn A Huestis
Journal:  Curr Top Behav Neurosci       Date:  2017

3.  Quantification of Synthetic Cathinones in Rat Brain Using HILIC-ESI-MS/MS.

Authors:  Jacob R Peters; Robert Keasling; Stacy D Brown; Brooks B Pond
Journal:  J Anal Toxicol       Date:  2016-07-29       Impact factor: 3.367

4.  Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems.

Authors:  Dino Luethi; Karolina E Kolaczynska; Melanie Walter; Masaki Suzuki; Kenner C Rice; Bruce E Blough; Marius C Hoener; Michael H Baumann; Matthias E Liechti
Journal:  J Psychopharmacol       Date:  2019-04-30       Impact factor: 4.153

5.  Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects.

Authors:  Sebastien Anizan; Marta Concheiro; Kurt R Lehner; Mohammad O Bukhari; Masaki Suzuki; Kenner C Rice; Michael H Baumann; Marilyn A Huestis
Journal:  Addict Biol       Date:  2014-12-05       Impact factor: 4.280

6.  Pharmacological mechanisms underlying the cardiovascular effects of the "bath salt" constituent 3,4-methylenedioxypyrovalerone (MDPV).

Authors:  Charles W Schindler; Eric B Thorndike; Masaki Suzuki; Kenner C Rice; Michael H Baumann
Journal:  Br J Pharmacol       Date:  2016-11-16       Impact factor: 8.739

7.  Chiral determination of 3,4-methylenedioxypyrovalerone enantiomers in rat serum.

Authors:  Michael D Hambuchen; Howard P Hendrickson; S Michael Owens
Journal:  Anal Methods       Date:  2016-12-22       Impact factor: 2.896

8.  Active vaccination attenuates the psychostimulant effects of α-PVP and MDPV in rats.

Authors:  Jacques D Nguyen; Paul T Bremer; Alex Ducime; Kevin M Creehan; Brent R Kisby; Michael A Taffe; Kim D Janda
Journal:  Neuropharmacology       Date:  2016-12-09       Impact factor: 5.250

9.  Behavioural, Pharmacokinetic, Metabolic, and Hyperthermic Profile of 3,4-Methylenedioxypyrovalerone (MDPV) in the Wistar Rat.

Authors:  Rachel R Horsley; Eva Lhotkova; Katerina Hajkova; Barbara Feriancikova; Michal Himl; Martin Kuchar; Tomas Páleníček
Journal:  Front Psychiatry       Date:  2018-04-24       Impact factor: 4.157

10.  Comprehensive review of the detection methods for synthetic cannabinoids and cathinones.

Authors:  Akira Namera; Maho Kawamura; Akihiro Nakamoto; Takeshi Saito; Masataka Nagao
Journal:  Forensic Toxicol       Date:  2015-03-06       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.